Saturday, June 15th
Session 1: Welcome Reception & Opening Keynote
18:00-20:00 Registration Open and Welcome Reception
20:00-20:45 Keynote Speaker: Matthias Gromeier (Duke)
“Oncolytic Poliovirus Against Recurrent Glioblastoma”
Sunday, June 16th
7:30-8:30 Breakfast
8:30-11:30
Session 2: Oncolytic Viral Therapy and Immunity
Chairs: Antonio Chiocca (Harvard University) & Brian Lichty (McMaster University)
8:30-8:50 Mike Caligiuri (Ohio State)
“NK cells and their role in HSV oncolysis”
8:55-9:15 Richard Vile (Mayo Clinic)
“VSV-based cDNA Immunotherapy for Tumor Recurrence.”
9:20-9:40 Antonio Chiocca (Harvard University)
“Histone deacetylase-mediated inhibition of HSV oncolysis”
9:45-10:05 Coffee Break
15 minute talks:
Samuel Rabkin (Harvard University)
“IL-12 Armed oHSV Therapy in an Immunocompetent Cancer Stem Cell Model”
Derek Clements (Dalhousie University)
“Gemcitabine Enhances the Efficacy of Reovirus-based Oncotherapy Through Anti-tumor Immunological Mechanisms”
Jonathan Pol (McMaster University)
“Preclinical Evaluation of an Oncolytic Maraba Virus Vaccine in a Simian Model”
Guy Ungerechts (Ruprecht-Karls-University)
“Measles Virus for Immunovirotherapy of Cancer”
Anne Kleijn (Erasmus MC)
“The efficacy of the oncolytic adenovirus Delta24-RGD in an immune competent glioma model is dependent on the induced anti-tumor immune response”
13:00-16:00
Session 3: Viral Engineering
Chairs: Noriyuki Kasahara (UCLA) & Kah Whye Peng (Mayo Clinic)
13:00-13:20 Balveen Kaur (Ohio State)
“Preclinical evaluation of 34.5ENVE as a treatment option for multiple solid tumors alone and in combination with bortezomib”
13:25-13:45 Joe Glorioso (University of Pittsburgh)
“Highly Selective HSV Virotherapy of Glioblastoma by Combining EGFR-Tumor Targeting and microRNA Blockade of Virus Replication in Normal Brain”
13:50-14:10 Kah Whye Peng (Mayo Clinic)
“VSV-MV hybrid viruses for increased potency and specificity”
14:15-14:35 Coffee Break
14:35-14:55 Noriyuki Kasahara (UCLA)
“Engineering Retroviruses as Replicating Vectors for Gene Therapy of Cancer”
17:00-20:00 Working Dinner and talks
Session 4: Delivery, Imaging and Toxicology
Chairs: Len Seymour (Oxford University) & Stephen Russell (Mayo Clinic)
17:00-17:20 Yuman Fong (Memorial Sloan-Kettering)
17:25-17:45 Steve Thorne (University of Pittsburgh)
“Imaging of Oncolytic Vaccinia Delivery”
17:50-18:10 Stephen Russell (Mayo Clinic)
15 minute talks:
Michael Barry (Mayo Clinic)
“Capture and Evasion of Natural Antibodies and Kupffer Cells By Adenoviruses”
Michelle Wilkinson (Institute of Cancer Research)
“Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus delays tumour growth and prolongs survival.”
Kim Bentrup (TU München)
“PET imaging of oncolytic VSV expressing the mutant HSV-1 thymidine kinase transgene in an orthotopic and immunocompetent HCC model”
Sergio Acuna (University of Toronto)
“Preclinical Safety Assessment of a Novel Oncolytic Vaccine: Toxicity Testing and Immune Monitoring of Maraba Virus in Cynomolgus Macaques”
Shruthi Naik (Mayo Clinic)
“A Comparative oncology approach to translation of Oncolytic virus therapy”
20:00-22:00 Poster Session #1
Monday, June 17th
7:30-8:30 Breakfast
8:30-11:30
Session 5: Interactions with Tumour Microenvironment
Chairs: John Bell (Ottawa Hospital) & David Stojdl (CHEO)
8:30-8:50 Andrea McCart (University of Toronto)
“Biting the hand that feeds: Oncolytic virus infection of tumour vasculature”
15 minute talks:
Carolina Ilkow (Ottawa Hospital Research Institute)
“Crosstalk between cancer cells and cancer-associated fibroblasts promotes oncolytic virus infection in tumours”
Hans Meisen (Ohio State)
“Vstat120 reduces the innate inflammatory response to infection and enhances oncolytic viral therapy for Glioblastoma”
Vicki Jennings (University of Leeds)
“Can Reovirus overcome the suppressive tumour microenvironment in ovarian ascites?”
9:55-10:15 Coffee Break
Jennifer Leddon (Ohio State)
“Antitumor Efficacy of Oncolytic Herpes Simplex Virotherapy is not Determined by Tumor Cell Susceptibility or Permissivity”
Miriam Bazan-Peregrino (Instituto Catalan de Oncología)
“Tumor-targeted oncolytic adenovirus armed with hyaluronidase VCN-01 is able to induce chemosensitization to gemcitabine”
Pooja Gupta (Iowa State University)
“Mammalian Orthoreovirus infection of hypoxic prostate tumor cells induces downregulation of HIF-1a and apoptotic tumor cell death.”
13:00-15:00
Session 6: Combination Therapies A
Chairs: Samuel Rabkin (Harvard University) & Len Seymour (Oxford University)
13:00-13:20 Gunnel Hallden (Barts Cancer Institute)
“The oncolytic mutant Ad∆∆ synergises with cytotoxic drugs through induction of apoptosis, attenuation of autophagy and aberrant mitosis in prostate and pancreatic cancer models.”
15 minute talks:
Tommy Alain (McGill University)
“Active-site mTOR inhibitors bolster HSV1 oncolysis of cancers with elevated eIF4E activity.”
Shawn Beug (CHEO)
“Potentiation of Smac mimetic compound cytotoxicity by oncolytic virotherapy”
Erik Haefner (Eramsus MC)
“Combination Treatment with DELTA24-RGD and Temozolomide Iinfluences Immune cell Subsets in a Murine Malignant Glioma Model”
Joe Conner (Virttu Biologics Ltd)
“Inhibitors of mTOR combine with oncolytic HSV1716 in vitro to enhance cancer cell death”
Karen Mossman (McMaster University)
“Mitoxantrone synergizes with oncolytic herpes simplex virus to regress established breast tumors in part by increasing recruitment of CD8+ T cells”
18:00-20:00 Working Dinner and talks
Session 7: Combination Therapies B
Chairs: Andrea McCart (U of Toronto) & Jean-Simon Diallo (Ottawa Hospital)
18:00-18:20 Grant McFadden (University of Florida)
“Ex Vivo Virotherapy with Myxoma Virus”
15 minute talks:
Paula Savola (University of Helsinki)
“Treatment of gastric cancer with an oncolytic adenovirus expressing a full-length anti-Her2 monoclonal antibody”
Antonio Marchini (German Cancer Research Center)
“Synergistic Combination of Valproic Acid and Oncolytic Parvovirus H-1PV as a Potential Therapy against Cervical and Pancreatic Carcinomas”
Martina Zimmermann (University Hospital Tuebingen)
“MeV-RII_HepG2, a persistently measles virus infected human hepatoma cell line, shows resistance towards secondary infections with MeV virotherapeutics”
Vladimir Beljanski (Vaccine & Gene Therapy Institute of Florida)
“Sensitization of therapy-resistant chronic lymphocytic leukemia cells
to vesicular stomatitis virus oncolysis”
20:00-22:00 Poster Session #2
Tuesday June 18th
7:30-8:30 Breakfast
8:30-11:30
Session 9: Mechanisms of Viral Replication
Chairs: Grant McFadden (University of Florida) & Stephen Russell (Mayo Clinic)
8:30-8:50 Clodagh O’shea (Salk Institute)
8:55-9:15 Kerry Fisher (PsiOxus Therapeutics Ltd)
“ColoAd1 a group B oncolytic adenovirus: pre-clinical assessment of potency, safety and selectivity.”
15 minute talks:
Dominik Wodarz (University of California Irvine)
“Spatial virus dynamics and the spread of oncolytic viruses”
Valery Grdzelishvili (University of North Carolina)
“Multiple Factors Determine Resistance of Pancreatic Cancer Cells to Vesicular Stomatitis Virus”
Faris Farassati (University of Kansas)
“Transcriptional Targeting of CD133+ Cancer Stem Cells by Oncolytic Viruses”
Michael Brown (Duke University)
“MAP-Kinase Signaling Facilitates Picornaviral Oncolysis Through a Novel Function of the MAP-Kinase Interacting Kinases (MNKs)”
Tanner Miest (Mayo Clinic)
“Virus entry pathway governs efficacy of mantle cell lymphoma radiovirotherapy”
John Poirier (Johns Hopkins University)
“Host determinants of Seneca Valley Virus cancer selective tropism”
13:00-16:00
Session 10: Clinical Trials
Chairs: Robert Coffin (Biovex founder) & David Kirn (Jennerex)
13:00-13:20 Karsten Geletneky (University Hospital Heidelberg)
“ParvOryx01-Trial (Oncolytic Parvovirus H-1 in patients with recurrent glioblastoma multiforme): experiences after completion of the first study arm”
13:25-13:45 Robert Coffin
15 minute talks:
Mitesh Borad (Mayo Clinic)
“First-in-Human Study of Vesicular Stomatitis Virus Human Interferon Beta in Patients With Advanced Hepatocellular Cancer”
Michael Burke (University of Minnesota)
“A Phase I Study of Seneca Valley Virus (NTX-010) in Children with Relapsed/Refractory Solid Tumors (ADVL0911): A Report of the Children’s Oncology Group”
Caroline Breitbach (Jennerex Inc)
“Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, for the Treatment of Patients with Advanced Tumors”
John Beadle (PsiOxus Therapeutics)
“A Phase I study of ColoAd1, an Ad11/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial solid tumours.”
Frank Tufaro (DNAtrix Inc)
“Oncolytic virus therapy for glioblastoma: Clinical progress with DNX-2401 (Delta-24-RGD)”
Doug Jolly (Tocagen Inc.)
“Toca 511 – a retroviral replicating vector in clinical trials for High Grade Glioma”
Ulrich Lauer (Medical University Hospital Tübingen)
“Virotherapy of peritoneal carcinomatosis.”
18:00-20:00 Farewell Banquet